慢性阻塞性肺疾病急性加重与心血管事件:SUMMIT随机临床试验的事后队列分析
该研究为SUMMIT随机临床试验的事后队列分析,纳入来自43个国家1368个中心的16,485例中重度COPD且合并心血管疾病或心血管风险增高的现吸烟者或既往吸烟者。急性加重定义为呼吸道症状加重需抗生素、全身糖皮质激素和/或住院治疗。主要复合终点为心血管死亡、心肌梗死、卒中、不稳定型心绞痛和短暂性脑缺血发作。结果显示急性加重后心血管事件风险升高,尤其急性加重后30天内(HR 3.8,95%CI 2.7-5.5),且升高持续至1年;住院急性加重后30天HR为9.9(95%CI 6.6-14.9)。作者认为应高度警惕急性加重后早期心血管事件。
要点
- COPD急性加重后30天内心血管事件风险升高(HR 3.8,95%CI 2.7-5.5),风险升高持续至急性加重后1年。
- 住院急性加重后30天内心血管事件风险更高(HR 9.9,95%CI 6.6-14.9),超过非住院急性加重后30天HR(3.8)的两倍。
- 适用人群为具有心血管疾病或心血管风险增高的现吸烟者或既往吸烟者中重度COPD患者。
- 急性加重定义为呼吸道症状加重需抗生素、全身糖皮质激素和/或住院治疗。
- 作者认为,患者和临床医生应对COPD急性加重后早期心血管事件保持高度警惕。
适用人群与场景
- SUMMIT试验的便利样本:来自43个国家1368个中心的中重度COPD现吸烟者或既往吸烟者,均患有心血管疾病或心血管风险增高。
诊断标准与关键阈值
- 急性加重定义:呼吸道症状加重,需要抗生素、全身糖皮质激素和/或住院治疗。
- 心血管事件复合终点:心血管死亡、心肌梗死、卒中、不稳定型心绞痛和短暂性脑缺血发作,所有事件均经裁定。
研究设计与关键结果
- 研究类型:SUMMIT随机临床试验的事后队列分析,样本量16,485例,来自43个国家1368个中心。
- 16,485例参与者中,4,704例至少发生1次急性加重,688例至少发生1次心血管事件。
- 急性加重后心血管事件风险升高,尤其急性加重后30天内(HR 3.8,95%CI 2.7-5.5),并持续升高至急性加重后1年。
- 住院急性加重后30天HR为9.9(95%CI 6.6-14.9),超过非住院急性加重后30天HR(3.8)的两倍。
证据类型、等级与局限
- 证据类型:随机临床试验的事后队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,患者和临床医生应对COPD急性加重后早期心血管事件保持高度警惕。
- 该分析提示,在具有心血管疾病或心血管风险增高的COPD患者中,急性加重(尤其住院急性加重)后30天内及至1年内应警惕后续心血管事件。
指南或共识出处
- SUMMIT试验(Study to Understand Mortality and Morbidity),临床试验注册号NCT 01313676。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, associated with acute inflammation, and may increase subsequent cardiovascular disease (CVD) risk.
OBJECTIVES: Determine whether AECOPD events are associated with increased risk of subsequent CVD.
METHODS: We performed a secondary cohort analysis of the SUMMIT (Study to Understand Mortality and Morbidity) trial, a convenience sample of current/former smokers with moderate COPD from 1,368 centers in 43 countries. All had CVD or increased CVD risk. AECOPD was defined as an increase in respiratory symptoms requiring treatment with antibiotics, systemic corticosteroids, and/or hospitalization. CVD events were a composite outcome of cardiovascular death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. All CVD events were adjudicated. Cox proportional hazards models compared the hazard for a CVD event before AECOPD versus after AECOPD.
MEASUREMENTS AND MAIN RESULTS: Among 16,485 participants in SUMMIT, 4,704 participants had at least one AECOPD and 688 had at least one CVD event. The hazard ratio (HR) for CVD events after AECOPD was increased, particularly in the first 30 days after AECOPD (HR, 3.8; 95% confidence interval, 2.7-5.5) and was elevated up to 1 year after AECOPD. The 30-day HR after hospitalized AECOPD was more than twofold greater (HR, 9.9; 95% confidence interval, 6.6-14.9).
CONCLUSIONS: In patients with COPD with CVD or risk factors for CVD, exacerbations confer an increased risk of subsequent CVD events, especially in hospitalized patients and within the first 30 days after exacerbation. Patients and clinicians should have heightened vigilance for early CVD events after AECOPD. Clinical trial registered with www.clinicaltrials.gov (NCT 01313676).
参考来源
- Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med. 2018. PMID: 29442524. doi:10.1164/rccm.201711-2239OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。